Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- December 15, 2021 Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH
- December 13, 2021 Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population
- November 29, 2021 Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
- November 18, 2021 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
- November 16, 2021 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
- November 15, 2021 Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
- November 12, 2021 Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback
- November 10, 2021 Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting
- November 8, 2021 Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results
- November 4, 2021 Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting
Displaying 1 - 10 of 40